title: Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction.
abstract: One of the primary goals of physicians treating patients presenting to a hospital with acute ST-segment elevation myocardial infarction is to restore the flow of blood in the infarct-related artery as quickly as possible. Prompt and successful reperfusion limits the size of the myocardial infarction, reduces left ventricular dysfunction, and improves the patient's chance of survival. Approximately two thirds of patients with ST-segment elevation myocardial infarction do not present to a hospital capable of conducting urgent direct percutaneous coronary intervention or cardiac surgery when it is needed. They must receive pharmacological reperfusion therapy, a combination of fibrinolytic, antiplatelet, and anticoagulant drugs. Earlier and simpler administration of pharmacological reperfusion therapy could result in significantly improved outcomes. Fibrinolytic therapy, in combination with adjunctive antithrombin therapy that is simpler and quicker to administer (e.g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin.
authors.affiliation: Division of Cardiology, Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA. marcohen@sbhcs.com
authors.forename: Marc
authors.initials: M
authors.lastname: Cohen
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D015912:Thrombolytic Therapy; D014481:United States
chemical_list: D000991:Antithrombins; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors